Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:24 PM
Ignite Modification Date:
2025-12-24 @ 5:24 PM
NCT ID:
NCT04126850
Eligibility Criteria:
Inclusion Criteria:
* New patient registered at Cipto Mangunkusumo Hospital since November 2019
* Patient diagnosed with non-infectious uveitis (with Behcet, VKH history)
* Patient idiopathic uveitis (proven to have negative result by available etiological uveitis work-ups)
* Minimum age: 18 years old
* Experience active inflammation in the past 180 days and or during patient registration following Standard Uveitis Nomenclature (SUN) guidelines, in at least:
* equal and or more than 2+ anterior chamber cells
* equal and or more than 2+ vitreous haze and/or
* active retinal/choroidal lesions
Exclusion Criteria:
* patients had taken probiotics supplement or antibiotics 3 months before sample collection
* or who experience prolonged diarrhea or constipation
* or undergone gastrointestinal surgery
* having any form of malignancy
* having a systemic disease such as hypertension, obesity, inflammatory bowel disease, or diabetes.
* Disagree to sign informed consent
* Uveitis is proven to be an infectious origin
* Pregnant patient
* Loss to follow up patient
Healthy volunteers are recruited for this study after giving consent with the following inclusion criteria:
* age: 18-50 years old (Man/Woman)
* having no health complaints or symptoms
* not in any long term medications
* having no history of allergy
* willing to cooperate in the study
* state of complete physical, mental and social well being
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04126850
Study Brief:
Protocol Section:
NCT04126850